CorMedix is a bio-pharmaceutical company that produces DefenCath, an antimicrobial catheter lock solution containing ...

The most common clinical signs and symptoms of CRBSI are inflammation or purulence at the catheter site, as well as the acute onset of fever, chills, and hypotension with no other apparent source ...

Unlocking CRBSI Treatment: Transforming Care with Microbial Combinations for Better Outcomes.NEWARK, Del, Oct. 18, 2023 (GLOBE NEWSWIRE) -- In 2022, the global catheter-related bloodstream ...

CRBSI can be diagnosed when colony counts are at least 3-fold higher in cultures of blood obtained via the CVC than in cultures of blood taken from a peripheral vein.

The CRBSI market size is estimated at $2.6bn in 2023. The market is increasing in size due to the increasing usage of catheters to treat patients undergoing chemotherapy, ...

The global CRBSI treatment market is on a significant growth trajectory, projected to experience a compound annual growth rate (CAGR) of 5.4% between 2025 and 2035. This growth is being propelled by ...

CRBSI are a major health care concern. Approximately 500,000 cases of CRBSI occur in the U.S. each year. The CDC estimates that up to 25% of patients with CRBSI will die.

The global CRBSI Treatment Market is projected to be valued at USD 1,718.0 Million in 2025 and is expected to reach USD 2,908 Million by 2035, registering a CAGR of 5.4% during the forecast period, ...

However, CRBSI rates have not dropped below 0.5 to 2.39 per 1,000 patient days despite rigorous attention to cleanliness and early signs of infection. While it ...

DefenCath ® (taurolidine and heparin) catheter lock solution is now available for inpatient use to reduce the incidence of catheter-related bloodstream infections (CRBSI), in adult patients with ...

Canadian study reveals no significant effect of driving distance to a nephrology practice on the rate and appropriate management of catheter-related bloodstream infections. Hemodialysis (HD ...

Results showed that DefenCath reduced the risk of CRBSI by 71% (95% CI, 38-86) compared with heparin (P =.0006).